Verseau Therapeutics

Macrophage checkpoint modulators, Monoclonals Antibodies

VTX-1218 RD oncology; 4+ undisclosed programs RD oncology

Verseau Therapeutics aims to develop a new class of immunotherapy treatments for cancer. Their scientific approach centers on repolarizing immune cells, macrophages, from an immuno-suppressive to a pro-inflammatory state. Polarizing macrophages to this state allows them to kill the cancer cells and activate other immune cells within the tumor microenvironment. They have identified and validated numerous targets that can regulate macrophages. Using human cells from patient-derived human tumors, they can determine mechanism of action and preclinical proof of concept for their candidates. Verseau Therapeutics’ cutting-edge technologies, deep biological understanding, and extensive cancer patient genomic data will help them in creating transformative immunotherapies.

Jobs:

News: